Peritoneal Cancer - Pipeline Insight, 2025: Emerging Intraperitoneal and Systemic Therapies Pave the Way for More Targeted and Durable Responses | DelveInsight

Peritoneal cancer, often arising as a primary malignancy or secondary spread from abdominal tumors, presents unique clinical challenges due to its diffuse nature and resistance to standard systemic therapies. Despite HIPEC and cytoreductive surgery being mainstays, recurrence and survival outcomes remain suboptimal.

As of 2025, the pipeline for peritoneal cancer is expanding beyond conventional cytotoxic agents. Over 65 innovative therapies-including targeted ADCs, immune checkpoint inhibitors, oncolytic viruses, and localized drug delivery platforms-are progressing through preclinical and clinical pipelines. Companies such as Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, and Shattuck Labs are advancing precision therapeutics, aiming to improve tumor localization, reduce systemic toxicity, and enhance immune engagement.

DelveInsight's "Peritoneal Cancer - Pipeline Insight, 2025" provides a detailed overview of the global pipeline, highlighting late-stage clinical trials, novel combinations with immunotherapy, and personalized approaches based on molecular profiling.

As research intensifies around intraperitoneal and immunomodulatory solutions, the peritoneal cancer space is poised for breakthroughs that could dramatically enhance survival and response durability in this hard-to-treat malignancy.

Interested in learning more about the current treatment landscape and the key drivers shaping the peritoneal cancer pipeline? Click here: https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Peritoneal Cancer Pipeline Report
• DelveInsight's peritoneal cancer pipeline analysis depicts a strong space with 60+ active players working to develop 65+ pipeline drugs for peritoneal cancer treatment.
• The leading peritoneal cancer companies include Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma, and others are evaluating their lead assets to improve the peritoneal cancer treatment landscape.
• Key peritoneal cancer pipeline therapies in various stages of development include Azenosertib, ZEN003694, XMT-1660, Tisotumab vedotin, STRO-002, SL-172154, SCB-313, RP12146, Radspherin, IMGN151, AB-1015, M6620, MDNA11, MEK162, and others.
• In April 2025, Biocon Biologics received FDA approval for JobevneTM (bevacizumab-nwgd), a biosimilar to Avastin®, for intravenous use. Jobevne is approved for multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and ovarian, fallopian tube, or primary peritoneal cancer.
• In February 2025, Serac Healthcare announced receiving positive feedback from the FDA following its End of Phase II Meeting for 99mTc-maraciclatide. This molecular imaging agent is being developed for use with SPECT-CT to visualize and diagnose superficial peritoneal endometriosis (SPE) in women aged 16 and older.

Request a sample and discover the recent breakthroughs happening in the peritoneal cancer pipeline landscape at https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peritoneal Cancer Overview
Peritoneal cancer is a rare and aggressive malignancy that arises from the peritoneum-the thin, protective membrane lining the abdominal cavity and covering abdominal organs. It can occur as a primary cancer, known as primary peritoneal carcinoma (PPC), or more commonly as a secondary cancer, resulting from the spread (metastasis) of malignancies such as ovarian, colorectal, gastric, or appendiceal cancers. Despite its close resemblance to advanced ovarian cancer in presentation and pathology, peritoneal cancer is a distinct clinical entity.

The disease typically presents with non-specific symptoms such as abdominal bloating, pain, early satiety, nausea, and unintentional weight loss, making early diagnosis challenging. Accumulation of fluid in the abdomen (ascites) is also common. Diagnosis often involves imaging, cytology of ascitic fluid, and sometimes diagnostic laparoscopy or biopsy.

Treatment strategies generally mirror those used for ovarian cancer and may include cytoreductive surgery combined with systemic chemotherapy or hyperthermic intraperitoneal chemotherapy (HIPEC). However, prognosis remains poor, especially in advanced stages, due to late detection and limited targeted therapies. Current research is focused on molecular profiling, targeted therapies, and immunotherapy approaches to improve outcomes for this difficult-to-treat cancer.

Find out more about peritoneal cancer medication at https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peritoneal Cancer Treatment Analysis: Drug Profile
Relacorilant: Corcept Therapeutics
Relacorilant is an investigational selective glucocorticoid receptor (GR) modulator being developed by Corcept Therapeutics, currently in Phase III clinical trials for the treatment of peritoneal cancer. The drug works by inhibiting cortisol activity at the GR, which may help overcome cortisol-driven resistance mechanisms that reduce the efficacy of chemotherapy and immunotherapy in solid tumors. In the context of peritoneal cancer-particularly high-grade serous carcinomas and malignancies with peritoneal metastases-Relacorilant is being evaluated in combination with agents like nab-paclitaxel. The combination is designed to enhance tumor sensitivity to chemotherapy. Early clinical data has shown encouraging signs of improved progression-free survival in select patient groups, with ongoing studies aimed at further validating its safety and clinical benefit.

Farletuzumab Ecteribulin (FZEC): Eisai Inc.
Farletuzumab ecteribulin (FZEC) is Eisai's first antibody-drug conjugate (ADC), currently in Phase II development for peritoneal cancer. It consists of farletuzumab, a humanized monoclonal antibody that targets folate receptor alpha (FRα), linked to eribulin, an anticancer agent and microtubule dynamics inhibitor. Upon binding to FRα-positive cancer cells, the linker is enzymatically cleaved inside the cell, releasing eribulin to exert its cytotoxic effects. Notably, FZEC has demonstrated a bystander effect in preclinical studies, showing efficacy against neighboring FRα-negative cells within the tumor microenvironment. This dual action may enhance its therapeutic potential in heterogeneous tumors like peritoneal cancer.

XMT-1660: Mersana Therapeutics
XMT-1660 is a next-generation antibody-drug conjugate (ADC) developed by Mersana Therapeutics, currently in Phase I trials for peritoneal cancer. It targets B7-H4 (VTCN1), a tumor-associated antigen widely expressed in breast, ovarian, and endometrial cancers, including peritoneal metastases. The drug employs Mersana's Dolasynthen platform and features a DAR-6 (drug-to-antibody ratio of 6), site-specifically conjugated with the DolaLock payload AF-HPA, a microtubule inhibitor with a controlled bystander effect. XMT-1660 is designed to not only attack B7-H4-positive tumor cells but also modulate the immunosuppressive tumor microenvironment, including tumor-associated macrophages. Its unique design aims to offer precise cytotoxicity with enhanced tumor penetration and immune modulation.

Learn more about the novel and emerging peritoneal cancer pipeline therapies at https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peritoneal Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Peritoneal Cancer Pipeline Report
• Coverage: Global
• Key Peritoneal Cancer Companies: Zentalis Pharmaceuticals, Zenith Epigenetics, Mersana Therapeutics, Seagen, Sutro Biopharma, Shattuck Labs, Clover Biopharmaceuticals, Rhizen Pharmaceutical, Oncoinvent, ImmunoGen, Arsenal Biosciences, EMD Serono Research & Development Institute, Medicenna Therapeutics, Array BioPharma, and others.
• Key Peritoneal Cancer Pipeline Therapies: Azenosertib, ZEN003694, XMT-1660, Tisotumab vedotin, STRO-002, SL-172154, SCB-313, RP12146, Radspherin, IMGN151, AB-1015, M6620, MDNA11, MEK162, and others.

Dive deep into rich insights for drugs used for peritoneal cancer treatment, visit: https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Peritoneal Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Peritoneal Cancer Pipeline Therapeutics
6. Peritoneal Cancer Pipeline: Late-Stage Products (Phase III)
7. Peritoneal Cancer Pipeline: Mid-Stage Products (Phase II)
8. Peritoneal Cancer Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.